Abstracts Archive - Page 1997 of 2607 - ACR Meeting Abstracts

Abstract Number: 1894 • 2015 ACR/ARHP Annual Meeting
Calcium Channel Blockers Are More Effective in the Treatment of Primary Raynaud’s Phenomenon Compared to Secondary: A Meta-Analyis
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Peter Tugwell⁶, Jordi Pardo⁷, Elizabeth Ghogomu⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of calcium channel blockers (CCBs) versus placebo for the treatment of Raynaud's phenomenon (RP) comparing primary to secondary…
Abstract Number: 1895 • 2015 ACR/ARHP Annual Meeting
Correlation of Scleroderma Interstitial Lung Disease with Gastroesophageal Reflux
Brady Bulian¹, W Leroy Griffing² and Michael Crowell³, ¹Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, ²Rheumatology, Mayo Clinic Arizona, Scottsdale, AZ, ³Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease involving the skin and visceral organs, most commonly the gastrointestinal tract and lungs. Interstitial lung disease…
Abstract Number: 1896 • 2015 ACR/ARHP Annual Meeting
Early Signs, Symptoms and Auto-Antibodies to Predict Diffuse Cutaneous or Limited Cutaneous Systemic Sclerosis at First Presentation
WMT van den Hombergh¹, HKA Knaapen-Hans¹, Patricia E. Carreira^2,3, FHJ van den Hoogen¹, Jaap Fransen¹ and MC Vonk¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³Rheumatology Unit, Hospital 12 de Octubre, Hospital 12 de Octubre, Madrid, Spain
ABSTRACT Background/Purpose: Diffuse cutaneous systemic sclerosis (dcSSc) is associated with a poorer prognosis compared to limited cutaneous SSc (lcSSc), due to earlier and more severe…
Abstract Number: 1897 • 2015 ACR/ARHP Annual Meeting
Fragmented Qrs Patterns Do Not Correlate with the Degree of Lung and Skin Involvement in Patients with Systemic Sclerosis
Didem Uzunaslan¹, Caner Saygin¹, Mehmet Kostek², Mehmet Ozdemir², Tufan Torun², Servet Altay³ and Gulen Hatemi⁴, ¹Cleveland Clinic, Cleveland, OH, ²Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ³Edirne Community Hospital, Edirne, Turkey, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey
Background/Purpose: Cardiac involvement is a common subclinical feature of systemic sclerosis (SSc) and results from the widespread fibrosis observed during disease course. Fragmented QRS (fQRS)…
Abstract Number: 1898 • 2015 ACR/ARHP Annual Meeting
Are There Risk Factors for Calcinosis in Scleroderma?
Sneha Pai¹ and Vivien Hsu², ¹Rheumatology, Robert Wood Johnson Medical School Hospital, New Brunswick, NJ, ²Medicine, Rutgers University, New Brunswick, NJ
Background/Purpose: Calcinosis is the deposition of calcium hydroxyapatite in the soft tissues in patients with scleroderma spectrum disorders (SSc). Risk factors are unknown and there…
Abstract Number: 1899 • 2015 ACR/ARHP Annual Meeting
Aortic Stenosis Is Increased in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Compared to Other Forms of Pulmonary Arterial Hypertension
María Martín López¹, Otto Martin Olivas Vergara², Mario Rodríguez³, Carmen D Merino⁴, Carmen Jiménez^5,6, Estibaliz Loza⁷, Pilar Escribano^5,6, Loreto Carmona⁸ and Patricia E. Carreira², ¹RHEUMATOLOGY, Hospital Universitario 12 de Octubre, Madrid, Spain, ²Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Fundación Hospital de Alcorcón, Madrid, Spain, ⁵Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Research Unit. Sociedad Española de Reumatología, Madrid, Spain, ⁸Instituto de Salud Musculoesquelética, Madrid, Spain
Background/Purpose: Degenerative aortic stenosis (DAS) is the most common form of valvular heart disease associated with advancing age. DAS pathophysiology has not been clearly elucidated,…
Abstract Number: 1900 • 2015 ACR/ARHP Annual Meeting
Performance of the Detect Protocol for Pulmonary Arterial Detection in Systemic Sclerosis Patients in Clinical Practice
Otto Martin Olivas Vergara¹, Beatriz E. Joven¹, Belen Diaz Anton², Carmen Jiménez², Maria Martin Lopez³, Pilar Escribano² and Patricia E. Carreira^1,2, ¹Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ²Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ³RHEUMATOLOGY, Hospital Universitario 12 de Octubre, Madrid, Spain
Background/Purpose: To analyze the usefulness of the DETECT protocol (1) for the prediction of pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) in routine clinical…
Abstract Number: 1901 • 2015 ACR/ARHP Annual Meeting
Association of Serum Adipokines Adipsin, Adiponectin, and Leptin/Adiponectin Ratio with Systemic Sclerosis
Benjamin Korman¹, Roberta Goncalves Marangoni¹, Monique E. Hinchcliff², Sanjiv Shah³, Mary A. Carns⁴, Rosalind Ramsey-Goldman⁵ and John Varga⁶, ¹Division of Rheumatology, Northwestern University, Chicago, IL, ²Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Chicago, IL, ⁴Rheumatology, Northwestern University, Chicago, IL, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
Background/Purpose: Patients with systemic sclerosis (SSc) display reductions in adipose tissue, particularly intradermal adipose tissue. There are currently no well-validated serum biomarkers in SSc, and…
Abstract Number: 1902 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis and Lung Cancer Risk: Data from the Canadian Scleroderma Research Group
Lama Sakr¹, Elie Younanian², Marie Hudson³, Mianbo Wang⁴, Murray Baron⁵ and Sasha Bernatsky⁶, ¹Division of Pulmonary Diseases, Jewish General Hospital, Montreal, QC, Canada, ²Division of Pulmonary Diseases, McGill University, Montreal, QC, Canada, ³McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁴Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The literature supports an increased incidence of certain malignancies in patients with systemic sclerosis (SSc), including lung cancers. Predictors of lung cancer in SSc…
Abstract Number: 1903 • 2015 ACR/ARHP Annual Meeting
Assessment of Subclinical Atherosclerosis in Patients with Systemic Sclerosis: Results from a Multicentric Cohort
Codrina Ancuta^1,2, Codruta Belibou³, Cristina Pomirleanu^1,4, Carina Mihai⁵, Ioan Ancuta⁵, Patricia E. Carreira⁶, Jose Luis Rosales Alexander⁷, Juan José Alegre⁸, Valeria Riccieri⁹, Maria J. Salvador¹⁰ and Rodica Chirieac⁴, ¹Rheumatology, Gr.T.Popa University of Medicine and Pharmacy, Iasi, Romania, ²Rheumatology 2, Clinical Rehablitation Hospital, Iasi, Romania, ³Research Department, Clinical Rehabilitation Hospital, Iasi, Romania, ⁴Rheumatology 2, Clinical Rehabilitation Hospital, Iasi, Romania, ⁵Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁶Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Hospiten Health Network, Tenerife, Spain, ⁸Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁹Cattedra di Reumatologia, Dip Clinica e Terapia Medica, Sapienza Università di Roma, Roma, Italy, ¹⁰Rheumatology, Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal
Background/Purpose: Although numerous studies have reported different findings on subclinical and definite atherosclerosis (AS) in autoimmune rheumatic diseases, data in systemic sclerosis (SSc) are still…
Abstract Number: 1904 • 2015 ACR/ARHP Annual Meeting
Development of the Mawdsley Calcinosis Questionnaire (MCQ) Version 1 – a Patient-Reported Outcome Measure (PROM) for Systemic Sclerosis Related Calcinosis (SSc-Ca)
Lesley Ann Saketkoo¹, Kim Fligelstone², Evan Busman³, Angela Christensen⁴, Sophia Cenac⁵, Samara Khalique⁶, Andrew Aubin⁷, Veronika K. Jaeger⁸, Anne Mawdsley⁹, Jessica K. Gordon¹⁰, Randi Kaufman¹¹, Murray Baron¹², Virginia D. Steen¹³ and Tracy M. Frech¹⁴, ¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ³Atlanta Scleroderma Support Group, Atlanta, GA, ⁴Tulane University School of Medicine, New Orleans, LA, ⁵Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, New Orleans, LA, ⁷Louisiana State University School of Medicine, New Orleans, LA, ⁸Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁹Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Lousiana State University Health Sciences Center - School of Public Health, New Orleans, LA, ¹²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Div of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: SSc-Ca is a poorly understood vascular complication of SSc that usually related to extreme constant pain and infection/amputation risk for persons living with SSc-Ca…
Abstract Number: 1905 • 2015 ACR/ARHP Annual Meeting
Stimulators of Soluble Guanylate Cyclase (sGC) Inhibit Experimental Skin Fibrosis of Different Aetiologies
Peter Sandner^1,2, Clara Dees³, Joerg H. W. Distler³, Christian Beyer³, Alfiya Distler³, Yun Zhang⁴, Katrin Palumbo-Zerr⁴, Georg A. Schett⁵, Alina Soare^3,6, Oliver Distler⁷ and Emanuel Haasbach⁸, ¹Bayer Health Care, Global Drug Discovery, Bayer Pharma AG, Wuppertal, Germany, ²Institute of Pharmacology, Hannover Medical School, Hannover, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology, Cantacuzino Hospital, Bucharest, Romania, ⁷Research of Systemic Autoimmune Diseases, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Bayer HealthCare, Bayer Pharma AG, Wuppertal, Germany
Background/Purpose: Systemic sclerosis (SSc) is characterised by fibrosis and vascular alterations, both of which account for the high morbidity and mortality of SSc. Although several…
Abstract Number: 1906 • 2015 ACR/ARHP Annual Meeting
Stimulators of Soluble Guanylate Cyclase (sGC) Improve Wound Healing in the Tsk-1 Mouse Skin Fibrosis Mode
Peter Sandner^1,2, Christian Beyer³, Joerg H. W. Distler³ and Emanuel Haasbach¹, ¹Bayer HealthCare, Bayer Pharma AG, Wuppertal, Germany, ²Institute of Pharmacology, Hannover Medical School, Hannover, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a multisystem disorder characterized by thickening of the skin and distinctive involvement of multiple internal organs. In addition to skin…
Abstract Number: 1907 • 2015 ACR/ARHP Annual Meeting
Inhibition of Phosphodiesterase 4 (PDE4) Reduces Dermal Fibrosis By Interfering with the Release of Pro-Fibrotic Cytokines from M2-Macrophages
Christiane Maier, Christian Beyer, Jeorg HW Distler and Georg Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: PDE4 catalyses the breakdown of the second messengers cAMP and cGMP to modulate intracellular effects. PDE4 is mainly expressed in inflammatory cells, and its…
Abstract Number: 1908 • 2015 ACR/ARHP Annual Meeting
Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with Altered Tgfbeta/BMPR2 Signalling
Emma C. Derrett-Smith¹, Vincent Sobanski², Adrian Gilbane², Sarah Trinder³, Yasmina Bauer⁴, Berengère Renault⁴, Marc Iglarz⁴, David Abraham⁵, Alan M. Holmes⁶ and Christopher P. Denton⁷, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Division of Medicine, London, United Kingdom, ²UCL Division of Medicine, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Disease, UCL Division of Medicine, London, United Kingdom, ⁴Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, ⁵Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ⁷Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is an important complication of systemic sclerosis (SSc) that occurs in around 10% of cases. We have previously shown that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].